Literature DB >> 12799050

Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR.

Sébastien Dall'Ozzo1, Christian Andres, Pierre Bardos, Hervé Watier, Gilles Thibault.   

Abstract

A polymorphism at position 559 in the cDNA of the FCGR3A gene encoding the FcgammaRIIIa generates two allotypes with either a valine (Val) or a phenylalanine (Phe) at amino acid position 158. This polymorphism is of major importance in immunopathology and in pharmacogenetics, especially monoclonal antibody treatments. In this study, we report a single-step and single-tube method for FCGR3A-158V/F genotyping by real-time multiplex allele-specific PCR and melting curve analysis in the presence of SYBR Green I fluorescent dye. Results obtained from 113 samples showed 100% accuracy compared to those obtained with a conventional PCR-based allele-specific restriction assay. Although this method requires expensive equipment, it is inexpensive in terms of consumables. It is also very rapid, reliable and suitable for large-scale analysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799050     DOI: 10.1016/s0022-1759(03)00123-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  14 in total

1.  Association of Fcγ receptor IIIA variant with a subset of anti-topoisomerase I-positive patients in systemic sclerosis: a descriptive pilot study.

Authors:  J Magnant; M Ohresser; Y Allanore; M de Monte; M Lafosse-Marin; D Degenne; J L Guilmot; H Watier; E Diot
Journal:  Rheumatol Int       Date:  2011-07-23       Impact factor: 2.631

2.  Pyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques.

Authors:  Ksenia Matlawska-Wasowska; James M Gale; Christian K Nickl; Parisa Khalili; Brian Shirley; Bridget S Wilson; Mohammad A Vasef; Stuart S Winter
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

3.  Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Authors:  Mira Tout; Anne-Laure Gagez; Stéphane Leprêtre; Valérie Gouilleux-Gruart; Nicolas Azzopardi; Alain Delmer; Mélanie Mercier; Loïc Ysebaert; Kamel Laribi; Hugo Gonzalez; Gilles Paintaud; Guillaume Cartron; David Ternant
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

4.  Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.

Authors:  David Ternant; Zahir Berkane; Laurence Picon; Valérie Gouilleux-Gruart; Jean-Frédéric Colombel; Matthieu Allez; Edouard Louis; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

5.  Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Authors:  Donald N Forthal; Erin E Gabriel; Angela Wang; Gary Landucci; Tran B Phan
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

6.  Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaRIIIa genetic polymorphism.

Authors:  David Ternant; Matthias Büchler; Maud Bénéton; Gunnar Alván; Marc Ohresser; Guy Touchard; Bruno Hurault de Ligny; Olivier Toupance; Hervé Watier; Yvon Lebranchu; Gilles Paintaud
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

Review 7.  Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.

Authors:  Tara M Robinson; Paul V O'Donnell; Ephraim J Fuchs; Leo Luznik
Journal:  Semin Hematol       Date:  2016-01-15       Impact factor: 3.851

8.  Melt analysis of mismatch amplification mutation assays (Melt-MAMA): a functional study of a cost-effective SNP genotyping assay in bacterial models.

Authors:  Dawn N Birdsell; Talima Pearson; Erin P Price; Heidie M Hornstra; Roxanne D Nera; Nathan Stone; Jeffrey Gruendike; Emily L Kaufman; Amanda H Pettus; Audriana N Hurbon; Jordan L Buchhagen; N Jane Harms; Gvantsa Chanturia; Miklos Gyuranecz; David M Wagner; Paul S Keim
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

9.  Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.

Authors:  Heiner Zimmermann; Theresa Weiland; Jamie P Nourse; Maher K Gandhi; Petra Reinke; Ruth Neuhaus; Mohsen Karbasiyan; Barbara Gärtner; Ioannis Anagnostopoulos; Hanno Riess; Ralf U Trappe; Stephan Oertel
Journal:  J Immunol Res       Date:  2014-02-10       Impact factor: 4.818

10.  Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.

Authors:  Haibo Sun; Thomas G Martin; John Marra; Denice Kong; Jonathon Keats; Sandrine Macé; Marielle Chiron; Jeffrey L Wolf; Jeffrey M Venstrom; Raja Rajalingam
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.